diABZI-V/C-DBCO is a STING agonist with an EC 50 of 1.47 nM. diABZI-V/C-DBCO activates the STING pathway, induces the production of IFN-I , and stimulates the secretion of IFN-β . diABZI-V/C-DBCO serves as a substrate for cathepsin B , and releases active diABZI-amine via cathepsin B-mediated cleavage. In an orthotopic mouse model of breast cancer , diABZI-V/C-DBCO increases serum IFN-β levels and the frequency of granzyme B + CD8 + T cells. diABZI-V/C-DBCO is applicable to research related to triple-negative breast cancer .
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > STING | Products > Signaling Pathways > IFNAR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.